Evidence map›Paper›PMID 40512690›Full record

ArticlePloS one2025

Progress towards the 95-95-95 targets to end HIV by 2030 in Lebanon, 2023.

Mohammed Gouda ElMedrek, Joumana Hermez, Yvan Hutin, Abdinasir Abubakar, Ghada Muhjazi, Emmanuel Olatunji, Muhammad Shahid Jamil, Ahmed Sabry Alaama, Nevin Wilson, Firass Abiad and 2 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Clinical management of XpertBMC infectious diseases · 2026
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mohammed Gouda ElMedrekWorld Health Organization (WHO), Regional Office for the Eastern Mediterranean Region, Cairo, Egypt.ORCID 0009-0001-7142-2353
Joumana HermezWorld Health Organization (WHO), Regional Office for the Eastern Mediterranean Region, Cairo, Egypt.
Yvan HutinWorld Health Organization (WHO), Regional Office for the Eastern Mediterranean Region, Cairo, Egypt.
Abdinasir AbubakarWHO, Country Office for Lebanon, Beirut, Lebanon.ORCID 0000-0002-5131-5518
Ghada MuhjaziWorld Health Organization (WHO), Regional Office for the Eastern Mediterranean Region, Cairo, Egypt.
Emmanuel OlatunjiThe Global Fund, Africa and Middle East (AME) Department, Grant Management Division, Geneva, Switzerland.
Muhammad Shahid JamilWorld Health Organization (WHO), Regional Office for the Eastern Mediterranean Region, Cairo, Egypt.
Ahmed Sabry AlaamaWorld Health Organization (WHO), Regional Office for the Eastern Mediterranean Region, Cairo, Egypt.
Nevin WilsonInternational Organization for Migration, Amman, Jordan.ORCID 0000-0002-0191-8855
Firass AbiadMinistry of Public Health, Beirut, Lebanon.
Hiam YaacoubMinistry of Public Health, Beirut, Lebanon.
Mostafa El NakibNational AIDS Programme Manager, NAP, Beirut, Lebanon.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundLebanon faces an HIV epidemic concentrated in key populations. The national AIDS programme [NAP] hosted by WHO since 1989 achieved substantial progress towards the 95-95-95 UNAIDS targets. In 2023, we reviewed the programme to guide its planned transition back into the structure of the Ministry of Health [MOH].

methodsIn 2023, we reviewed programme documents, epidemiological information and interviewed relevant stakeholders. We compiled national data along with WHO and UNAIDS estimates to describe the evolution of programme and epidemiological indicators, along with the result chain of input, process, output, outcome and impact.

resultsDomestic funding for the NAP increased from 73% in 2007 to 97% in 2018, before a drop in 2019 because of the financial crisis, when the NAP became dependent on international funding, including the Global Fund (commodities and services) and WHO (human resources). NAP core functions were governance, capacity building, monitoring and evaluation, anti-retro viral treatment [ART] dispensing and follow up for persons living with HIV [PLHIV] with some involvement in procurement, supply chain and laboratory testing. The NAP provided prevention, diagnosis and treatment services through Civil Society Organizations [CSOs]. In 2022, in Lebanon, 86% of PLHIV were diagnosed, among which 93% were on treatment and 95% virally suppressed. In 2022, NAP reported 232 new HIV infections, a 41% increase since 2010 and a 25% decrease in AIDS-related deaths during the same period. The estimated HIV incidence increased 4.4 times among MSM from 2008 to 2019, remained zero among commercial sex workers, and evolved from 0 to 0.11 per 1,000 to 0.9 per 1,000 in 2021 among PWIDs.

conclusionsLebanon is on track to achieve the UNAIDS 95-95-95 by 2025 targets. After transition into the MoPH, the NAP will need to [1] identify ways to sustain its sources of domestic funding, [2] build on its collaborations with CSOs to expand prevention activities in key populations, and [3] address the evolving needs of the population, including among transgenders, migrants, displaced people, and refugees, 4) maintain good quality core functions (capacity building, monitoring and evaluation, and medications).

Indexed as

HIV InfectionsFemaleHumansLebanonMale

Identifiers

PMID40512690
PMCPMC12165419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.